


Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. Serial No. Applicant Filing Date Group IDS Filed	50111/043002 09/215,163 Stinson et al. December 18, 1998 1645 October 30, 2007
--	---	---	---

U. S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
/RAZ/	Bose et al., "High affinity mouse-human chimeric Fab against Hepatitis B surface antigen," <i>World J. Gastroenterol.</i> 11: 7569-7578 (2005).
/RAZ/	Edwards et al. Vero cell neutralization and mouse protective efficacy of humanized monoclonal antibodies against escherichia coli toxins Stx1 and Stx2. In: Kaper J., O'Brien A. D., editors. <i>Escherichia coli O157:H7 and Other Shiga Toxin-Producing E. coli Strains</i> . ASM Press, Washington (DC) 388-392 (1998).
/RAZ/	Morrison, "With FDA talks stalled, Thallion looks abroad," <i>BioWorld Today</i> 18: 1-7 (2007).

EXAMINER	/Robert Zeman/	DATE CONSIDERED	02/05/2008
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			